Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Up 11.2% in October

Innovent Biologics, Inc. (OTCMKTS:IVBXF) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,001,500 shares, an increase of 11.2% from the October 15th total of 2,699,000 shares. Based on an average daily trading volume, of 1,100 shares, the short-interest ratio is presently 2,728.6 days.

Innovent Biologics Stock Up 2.5 %

IVBXF stock opened at $4.58 on Monday. The stock’s 50 day simple moving average is $5.51 and its 200 day simple moving average is $5.19. Innovent Biologics has a fifty-two week low of $3.83 and a fifty-two week high of $6.40.

Innovent Biologics Company Profile

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.